ATE176152T1 - Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke - Google Patents

Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke

Info

Publication number
ATE176152T1
ATE176152T1 AT89904362T AT89904362T ATE176152T1 AT E176152 T1 ATE176152 T1 AT E176152T1 AT 89904362 T AT89904362 T AT 89904362T AT 89904362 T AT89904362 T AT 89904362T AT E176152 T1 ATE176152 T1 AT E176152T1
Authority
AT
Austria
Prior art keywords
drug
prodrug
fatty acid
carrier
brain barrier
Prior art date
Application number
AT89904362T
Other languages
English (en)
Inventor
Victor E Shashoua
Original Assignee
Victor E Shashoua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victor E Shashoua filed Critical Victor E Shashoua
Application granted granted Critical
Publication of ATE176152T1 publication Critical patent/ATE176152T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT89904362T 1988-02-26 1989-02-24 Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke ATE176152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/160,667 US4939174A (en) 1988-02-26 1988-02-26 Appetite suppression with dopamine-fatty acid conjugates

Publications (1)

Publication Number Publication Date
ATE176152T1 true ATE176152T1 (de) 1999-02-15

Family

ID=22577881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89904362T ATE176152T1 (de) 1988-02-26 1989-02-24 Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke

Country Status (10)

Country Link
US (1) US4939174A (de)
EP (1) EP0401301B1 (de)
JP (1) JP2959784B2 (de)
KR (1) KR100228456B1 (de)
AT (1) ATE176152T1 (de)
AU (1) AU635203B2 (de)
DE (1) DE68928920T2 (de)
DK (1) DK526189A (de)
FI (1) FI904207A7 (de)
WO (1) WO1989007938A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284876A (en) * 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
WO1992020362A1 (en) * 1991-05-14 1992-11-26 Shashoua Victor E Nerve growth peptides and uses therefor
FR2712888B1 (fr) * 1993-11-23 1996-02-09 Bioeurope Utilisation de alpha-D-alkylglucopyranosides et esters de ceux-ci pour la préparation de prodrogues capables de traverser la barrière hématoencéphalique, prodrogues obtenues et précurseurs de celles-ci.
DE4437502A1 (de) * 1993-12-02 1995-06-08 Basf Ag Hirudin-Konjugate aus Hirudin und lipophilen Verbindungen
DE69529054T2 (de) * 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
AUPM906594A0 (en) * 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5639858A (en) * 1995-03-22 1997-06-17 Tularik, Inc. Human signal transducer and binding assays
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
WO1997044026A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
IL125731A (en) * 1998-08-11 2004-06-20 Zvi Yehuda Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9930026D0 (en) * 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
ATE556706T1 (de) * 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
AU2003217791A1 (en) 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
CA2527024C (en) * 2003-05-28 2012-08-21 Paul Anziano Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7989499B2 (en) * 2005-02-09 2011-08-02 Mitotek, Llc Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1968591A4 (de) 2005-12-23 2010-02-17 Link Medicine Corp Behandlung von synucleinopathien
JP4745838B2 (ja) * 2006-01-27 2011-08-10 株式会社Ｔａｉｙｏ 電動アクチュエータの制御方法及び装置
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US10167263B2 (en) 2008-11-20 2019-01-01 Northwestern University Treatment of amyotrophic lateral sclerosis
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
EP3144299A1 (de) 2009-05-05 2017-03-22 Cambria Pharmaceuticals, Inc. Pyrimidin-2,4,6-trione für die behandlung von amyotropher lateralsklerose
EP2438059A1 (de) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinonderivate und ihre verwendung
WO2011059821A2 (en) 2009-10-29 2011-05-19 Cambria Pharmaceuticals, Inc. Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis
CN103180297A (zh) 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
FR2964866B1 (fr) * 2010-09-22 2013-03-29 Oreal Utilisation comme antipelliculaire de derives ortho-diphenol, nouveaux composes et composition cosmetique les comprenant
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
EP3008167A4 (de) 2013-06-13 2017-06-07 VeroScience LLC Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
CA3007641C (en) 2015-12-09 2023-10-17 Brandeis University Dbh inhibitors for treating or preventing memory loss
AU2022215936A1 (en) * 2021-02-03 2023-08-24 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds

Also Published As

Publication number Publication date
FI904207A0 (fi) 1990-08-24
JPH03503893A (ja) 1991-08-29
EP0401301A4 (en) 1991-09-04
DE68928920D1 (de) 1999-03-11
EP0401301A1 (de) 1990-12-12
AU3354689A (en) 1989-09-22
JP2959784B2 (ja) 1999-10-06
DE68928920T2 (de) 1999-07-22
WO1989007938A1 (en) 1989-09-08
DK526189D0 (da) 1989-10-24
AU635203B2 (en) 1993-03-18
DK526189A (da) 1989-12-12
KR100228456B1 (ko) 1999-11-01
FI904207A7 (fi) 1990-08-24
KR900700092A (ko) 1990-08-11
US4939174A (en) 1990-07-03
EP0401301B1 (de) 1999-01-27

Similar Documents

Publication Publication Date Title
ATE176152T1 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
DE69521521T2 (de) Mono- oder polyfunktionelle konjugate von polylysine
KR940003057B1 (ko) 경구적(Oral) 전달방법
ES2048594T3 (es) Formulaciones farmaceuticas.
US8658632B2 (en) Arachidonic acid analogs and methods for analgesic treatment using same
DE3686936D1 (de) Am zielorgan wirkendes enterales abgabesystem.
DE69009185D1 (de) Arzneimittelfreisetzungssystem aus glucan und adjuvant.
ATE326867T1 (de) Freie aminosäure enthaltende zusammensetzung
KR920703558A (ko) 메타-치환 페닐알라닌 유도체
JP2010518113A (ja) アンフェタミンおよび他の刺激薬の極性親水性プロドラッグ、およびそれらの製造方法および使用方法
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
KR970025615A (ko) 암 전이 억제제
FI101377B1 (fi) Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi
RU2003125370A (ru) Новые рецепторы для helicobacter pylori и их применение
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
US5830432A (en) Phospholipid drug derivatives
Merhi et al. Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives
EP0561597A1 (de) Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen
CN100415801C (zh) 聚乙二醇氨基酸n-内环羰酐活性衍生物及其药物键合物和凝胶
JPH045231A (ja) 慢性痛用鎮痛剤
JP2006515622A (ja) 規制物質の乱用を防止するための炭水化物共役体
CO5170447A1 (es) Derivado de benzamida y medicamento que lo contiene
CA1336528C (fr) Derives d'aminoquinoleine antimalarique, procede de preparation et composition pharmaceutique en contenant
ATE45284T1 (de) Wirkstoff-vorlaeufer enthaltende pharmazeutische zusammensetzungen, verfahren zu ihrer herstellung, verfahren zur herstellung von wirkstoff-vorlaeufer-verbindungen und die erhaltenen verbindungen.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time